Global Immunotherapy for Neuroblastoma Supply, Demand and Key Producers, 2023-2029

Global Immunotherapy for Neuroblastoma Supply, Demand and Key Producers, 2023-2029

The global Immunotherapy for Neuroblastoma market size is expected to reach $ 63 million by 2029, rising at a market growth of 4.4% CAGR during the forecast period (2023-2029).

Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient's age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.

This report studies the global Immunotherapy for Neuroblastoma demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Immunotherapy for Neuroblastoma, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Immunotherapy for Neuroblastoma that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Immunotherapy for Neuroblastoma total market, 2018-2029, (USD Million)

Global Immunotherapy for Neuroblastoma total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Immunotherapy for Neuroblastoma total market, key domestic companies and share, (USD Million)

Global Immunotherapy for Neuroblastoma revenue by player and market share 2018-2023, (USD Million)

Global Immunotherapy for Neuroblastoma total market by Type, CAGR, 2018-2029, (USD Million)

Global Immunotherapy for Neuroblastoma total market by Application, CAGR, 2018-2029, (USD Million)

This reports profiles major players in the global Immunotherapy for Neuroblastoma market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, Ingenus Pharmaceuticals, Pfizer, Hikma Pharmaceuticals and Teva Pharmaceuticals, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Immunotherapy for Neuroblastoma market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Immunotherapy for Neuroblastoma Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Immunotherapy for Neuroblastoma Market, Segmentation by Type
Dinutuximab
Naxitamab
Other

Global Immunotherapy for Neuroblastoma Market, Segmentation by Application
Hospital
Clinic
Other

Companies Profiled:
United Therapeutics
Y-mAbs Therapeutics
EUSA Pharma
ANI Pharmaceuticals
Baxter Healthcare
Ingenus Pharmaceuticals
Pfizer
Hikma Pharmaceuticals
Teva Pharmaceuticals

Key Questions Answered

1. How big is the global Immunotherapy for Neuroblastoma market?

2. What is the demand of the global Immunotherapy for Neuroblastoma market?

3. What is the year over year growth of the global Immunotherapy for Neuroblastoma market?

4. What is the total value of the global Immunotherapy for Neuroblastoma market?

5. Who are the major players in the global Immunotherapy for Neuroblastoma market?

6. What are the growth factors driving the market demand?